Key Points
- Insider sale: On May 4, insider James Kihara sold 1,332 shares of ACAD at an average price of $21.79 for $29,024.28, trimming his position by 4.37% to 29,129 shares valued at roughly $634,721; he also sold 1,030 shares on April 7 at $22.20.
- Strong quarterly results: ACADIA reported Q4 EPS of $1.60 (vs. $0.12 consensus) and revenue of $298 million, up 9.4% year‑over‑year, with a 36.49% net margin and 12.49% ROE.
- Market view and ownership: Analysts' average rating is "Moderate Buy" with a $31.21 average price target, and institutional investors own about 96.71% of the company.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) insider James Kihara sold 1,332 shares of the firm's stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $21.79, for a total transaction of $29,024.28. Following the transaction, the insider owned 29,129 shares in the company, valued at $634,720.91. This represents a 4.37% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
James Kihara also recently made the following trade(s):
- On Tuesday, April 7th, James Kihara sold 1,030 shares of ACADIA Pharmaceuticals stock. The shares were sold at an average price of $22.20, for a total transaction of $22,866.00.
ACADIA Pharmaceuticals Price Performance
NASDAQ ACAD opened at $22.35 on Wednesday. ACADIA Pharmaceuticals Inc. has a 12 month low of $14.45 and a 12 month high of $28.35. The firm has a market capitalization of $3.83 billion, a PE ratio of 9.76, a P/E/G ratio of 23.15 and a beta of 0.86. The company's 50 day simple moving average is $22.16 and its 200 day simple moving average is $23.88.
ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last posted its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported $1.60 EPS for the quarter, beating analysts' consensus estimates of $0.12 by $1.48. ACADIA Pharmaceuticals had a net margin of 36.49% and a return on equity of 12.49%. The business had revenue of $298.00 million for the quarter, compared to analyst estimates of $292.54 million. During the same quarter last year, the business earned $0.86 earnings per share. The business's revenue for the quarter was up 9.4% on a year-over-year basis. Sell-side analysts anticipate that ACADIA Pharmaceuticals Inc. will post 0.45 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
ACAD has been the topic of a number of research analyst reports. Wall Street Zen lowered shares of ACADIA Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday, January 31st. Citizens Jmp raised their target price on shares of ACADIA Pharmaceuticals from $34.00 to $35.00 and gave the stock a "market outperform" rating in a report on Thursday, February 26th. TD Cowen raised their target price on shares of ACADIA Pharmaceuticals from $35.00 to $37.00 and gave the stock a "buy" rating in a report on Thursday, February 26th. Stifel Nicolaus reduced their target price on shares of ACADIA Pharmaceuticals from $25.00 to $24.00 and set a "hold" rating for the company in a report on Thursday, February 26th. Finally, Oppenheimer restated a "market perform" rating on shares of ACADIA Pharmaceuticals in a report on Friday, February 6th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $31.21.
View Our Latest Stock Analysis on ACAD
Institutional Investors Weigh In On ACADIA Pharmaceuticals
Several hedge funds have recently made changes to their positions in ACAD. Braidwell LP purchased a new stake in shares of ACADIA Pharmaceuticals in the 3rd quarter valued at approximately $50,760,000. Norges Bank purchased a new stake in shares of ACADIA Pharmaceuticals in the 4th quarter valued at approximately $40,266,000. Millennium Management LLC lifted its position in shares of ACADIA Pharmaceuticals by 2,052.1% in the 3rd quarter. Millennium Management LLC now owns 1,483,235 shares of the biopharmaceutical company's stock valued at $31,652,000 after acquiring an additional 1,414,315 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its position in shares of ACADIA Pharmaceuticals by 390.1% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,648,864 shares of the biopharmaceutical company's stock valued at $35,187,000 after acquiring an additional 1,312,426 shares in the last quarter. Finally, Logos Global Management LP purchased a new stake in shares of ACADIA Pharmaceuticals in the 4th quarter valued at approximately $22,704,000. Hedge funds and other institutional investors own 96.71% of the company's stock.
About ACADIA Pharmaceuticals
(
Get Free Report)
ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA's research centers concentrate on conditions with significant unmet medical needs, including Parkinson's disease psychosis, Alzheimer's disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.
The company's flagship product, NUPLAZID® (pimavanserin), received U.S.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
